Cargando…

Pre-clinical and Clinical Implications of “Inside-Out” vs. “Outside-In” Paradigms in Multiple Sclerosis Etiopathogenesis

Multiple Sclerosis (MS) is an immune-mediated neurological disorder, characterized by central nervous system (CNS) inflammation, oligodendrocyte loss, demyelination, and axonal degeneration. Although autoimmunity, inflammatory demyelination and neurodegeneration underlie MS, the initiating event has...

Descripción completa

Detalles Bibliográficos
Autores principales: Titus, Haley E., Chen, Yanan, Podojil, Joseph R., Robinson, Andrew P., Balabanov, Roumen, Popko, Brian, Miller, Stephen D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654287/
https://www.ncbi.nlm.nih.gov/pubmed/33192332
http://dx.doi.org/10.3389/fncel.2020.599717
_version_ 1783608035766173696
author Titus, Haley E.
Chen, Yanan
Podojil, Joseph R.
Robinson, Andrew P.
Balabanov, Roumen
Popko, Brian
Miller, Stephen D.
author_facet Titus, Haley E.
Chen, Yanan
Podojil, Joseph R.
Robinson, Andrew P.
Balabanov, Roumen
Popko, Brian
Miller, Stephen D.
author_sort Titus, Haley E.
collection PubMed
description Multiple Sclerosis (MS) is an immune-mediated neurological disorder, characterized by central nervous system (CNS) inflammation, oligodendrocyte loss, demyelination, and axonal degeneration. Although autoimmunity, inflammatory demyelination and neurodegeneration underlie MS, the initiating event has yet to be clarified. Effective disease modifying therapies need to both regulate the immune system and promote restoration of neuronal function, including remyelination. The challenge in developing an effective long-lived therapy for MS requires that three disease-associated targets be addressed: (1) self-tolerance must be re-established to specifically inhibit the underlying myelin-directed autoimmune pathogenic mechanisms; (2) neurons must be protected from inflammatory injury and degeneration; (3) myelin repair must be engendered by stimulating oligodendrocyte progenitors to remyelinate CNS neuronal axons. The combined use of chronic and relapsing remitting experimental autoimmune encephalomyelitis (C-EAE, R-EAE) (“outside-in”) as well as progressive diphtheria toxin A chain (DTA) and cuprizone autoimmune encephalitis (CAE) (“inside-out”) mouse models allow for the investigation and specific targeting of all three of these MS-associated disease parameters. The “outside-in” EAE models initiated by myelin-specific autoreactive CD4(+) T cells allow for the evaluation of both myelin-specific tolerance in the absence or presence of neuroprotective and/or remyelinating agents. The “inside-out” mouse models of secondary inflammatory demyelination are triggered by toxin-induced oligodendrocyte loss or subtle myelin damage, which allows evaluation of novel therapeutics that could promote remyelination and neuroprotection in the CNS. Overall, utilizing these complementary pre-clinical MS models will open new avenues for developing therapeutic interventions, tackling MS from the “outside-in” and/or “inside-out”.
format Online
Article
Text
id pubmed-7654287
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-76542872020-11-13 Pre-clinical and Clinical Implications of “Inside-Out” vs. “Outside-In” Paradigms in Multiple Sclerosis Etiopathogenesis Titus, Haley E. Chen, Yanan Podojil, Joseph R. Robinson, Andrew P. Balabanov, Roumen Popko, Brian Miller, Stephen D. Front Cell Neurosci Neuroscience Multiple Sclerosis (MS) is an immune-mediated neurological disorder, characterized by central nervous system (CNS) inflammation, oligodendrocyte loss, demyelination, and axonal degeneration. Although autoimmunity, inflammatory demyelination and neurodegeneration underlie MS, the initiating event has yet to be clarified. Effective disease modifying therapies need to both regulate the immune system and promote restoration of neuronal function, including remyelination. The challenge in developing an effective long-lived therapy for MS requires that three disease-associated targets be addressed: (1) self-tolerance must be re-established to specifically inhibit the underlying myelin-directed autoimmune pathogenic mechanisms; (2) neurons must be protected from inflammatory injury and degeneration; (3) myelin repair must be engendered by stimulating oligodendrocyte progenitors to remyelinate CNS neuronal axons. The combined use of chronic and relapsing remitting experimental autoimmune encephalomyelitis (C-EAE, R-EAE) (“outside-in”) as well as progressive diphtheria toxin A chain (DTA) and cuprizone autoimmune encephalitis (CAE) (“inside-out”) mouse models allow for the investigation and specific targeting of all three of these MS-associated disease parameters. The “outside-in” EAE models initiated by myelin-specific autoreactive CD4(+) T cells allow for the evaluation of both myelin-specific tolerance in the absence or presence of neuroprotective and/or remyelinating agents. The “inside-out” mouse models of secondary inflammatory demyelination are triggered by toxin-induced oligodendrocyte loss or subtle myelin damage, which allows evaluation of novel therapeutics that could promote remyelination and neuroprotection in the CNS. Overall, utilizing these complementary pre-clinical MS models will open new avenues for developing therapeutic interventions, tackling MS from the “outside-in” and/or “inside-out”. Frontiers Media S.A. 2020-10-27 /pmc/articles/PMC7654287/ /pubmed/33192332 http://dx.doi.org/10.3389/fncel.2020.599717 Text en Copyright © 2020 Titus, Chen, Podojil, Robinson, Balabanov, Popko and Miller. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Titus, Haley E.
Chen, Yanan
Podojil, Joseph R.
Robinson, Andrew P.
Balabanov, Roumen
Popko, Brian
Miller, Stephen D.
Pre-clinical and Clinical Implications of “Inside-Out” vs. “Outside-In” Paradigms in Multiple Sclerosis Etiopathogenesis
title Pre-clinical and Clinical Implications of “Inside-Out” vs. “Outside-In” Paradigms in Multiple Sclerosis Etiopathogenesis
title_full Pre-clinical and Clinical Implications of “Inside-Out” vs. “Outside-In” Paradigms in Multiple Sclerosis Etiopathogenesis
title_fullStr Pre-clinical and Clinical Implications of “Inside-Out” vs. “Outside-In” Paradigms in Multiple Sclerosis Etiopathogenesis
title_full_unstemmed Pre-clinical and Clinical Implications of “Inside-Out” vs. “Outside-In” Paradigms in Multiple Sclerosis Etiopathogenesis
title_short Pre-clinical and Clinical Implications of “Inside-Out” vs. “Outside-In” Paradigms in Multiple Sclerosis Etiopathogenesis
title_sort pre-clinical and clinical implications of “inside-out” vs. “outside-in” paradigms in multiple sclerosis etiopathogenesis
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654287/
https://www.ncbi.nlm.nih.gov/pubmed/33192332
http://dx.doi.org/10.3389/fncel.2020.599717
work_keys_str_mv AT titushaleye preclinicalandclinicalimplicationsofinsideoutvsoutsideinparadigmsinmultiplesclerosisetiopathogenesis
AT chenyanan preclinicalandclinicalimplicationsofinsideoutvsoutsideinparadigmsinmultiplesclerosisetiopathogenesis
AT podojiljosephr preclinicalandclinicalimplicationsofinsideoutvsoutsideinparadigmsinmultiplesclerosisetiopathogenesis
AT robinsonandrewp preclinicalandclinicalimplicationsofinsideoutvsoutsideinparadigmsinmultiplesclerosisetiopathogenesis
AT balabanovroumen preclinicalandclinicalimplicationsofinsideoutvsoutsideinparadigmsinmultiplesclerosisetiopathogenesis
AT popkobrian preclinicalandclinicalimplicationsofinsideoutvsoutsideinparadigmsinmultiplesclerosisetiopathogenesis
AT millerstephend preclinicalandclinicalimplicationsofinsideoutvsoutsideinparadigmsinmultiplesclerosisetiopathogenesis